Transfusion support in hematopoietic stem cell transplantation

Blood Res. 2023 Apr 30;58(S1):S1-S7. doi: 10.5045/br.2023.2023004. Epub 2023 Feb 27.

Abstract

Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.

Keywords: ABO blood group; Hematopoietic stem cell transplantation; RhD blood group; Transfusion.

Publication types

  • Review

Grants and funding

*This study was supported by a grant from National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2021R1F1A1046464).